NeuroBo Pharmaceuticals to Present at the Emerging Growth Conference in July

Rhea-AI Summary

NeuroBo Pharmaceuticals (Nasdaq: NRBO), a clinical-stage biotech company, will present at the Emerging Growth Conference on July 18, 2024, at 10:50 am ET. Hyung Heon Kim, President and CEO, along with Marshall H. Woodworth, CFO, will provide an overview of the company's work. The focus will be on DA-1726, a novel dual OXM agonist targeting GLP1R and GCGR receptors for obesity treatment. The session will include a Q&A segment, with questions to be submitted in advance or during the event. Register online to attend and receive updates. For additional meetings, contact Michael Miller.

CAMBRIDGE, Mass., July 11, 2024 /PRNewswire/ -- NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced that Hyung Heon Kim, President and Chief Executive Officer and Marshall H. Woodworth, Chief Financial Officer, will present a company overview at the Emerging Growth Conference on Thursday, July 18, 2024 at 10:50 am ET.

During the virtual presentation, management will provide an update on the clinical development of DA-1726, a novel, dual oxyntomodulin (OXM) analog agonist that functions as a glucagon-like peptide-1 receptor (GLP1R) and glucagon receptor (GCGR), for the treatment of obesity. 

After the presentation, NeuroBo management will open the floor for questions. Please submit your questions in advance to questions@emerginggrowth.com, or ask your questions during the event.

Please register using this link to attend the virtual conference and receive any updates that are released. To schedule a meeting with management outside of the conference, please contact Michael Miller at mmiller@rxir.com.

About NeuroBo Pharmaceuticals
NeuroBo Pharmaceuticals, Inc. is a clinical-stage biotechnology company focused on transforming cardiometabolic diseases. The company is currently developing DA-1726 for the treatment of obesity, and is developing DA-1241 for the treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH). DA-1726 is a novel oxyntomodulin (OXM) analogue that functions as a glucagon-like peptide-1 receptor (GLP1R) and glucagon receptor (GCGR) dual agonist. OXM is a naturally-occurring gut hormone that activates GLP1R and GCGR, thereby decreasing food intake while increasing energy expenditure, thus potentially resulting in superior body weight loss compared to selective GLP1R agonists. DA-1241 is a novel G-protein-coupled receptor 119 (GPR119) agonist that promotes the release of key gut peptides GLP-1, GIP, and PYY. In pre-clinical studies, DA-1241 demonstrated a positive effect on liver inflammation, lipid metabolism, weight loss, and glucose metabolism, reducing hepatic steatosis, hepatic inflammation, and liver fibrosis, while also improving glucose control.

For more information, please visit www.neurobopharma.com.

Contacts:

NeuroBo Pharmaceuticals
Marshall H. Woodworth
Chief Financial Officer
+1-857-299-1033
marshall.woodworth@neurobopharma.com

Rx Communications Group
Michael Miller
+1-917-633-6086
mmiller@rxir.com

 

View original content:https://www.prnewswire.com/news-releases/neurobo-pharmaceuticals-to-present-at-the-emerging-growth-conference-in-july-302194440.html

SOURCE NeuroBo Pharmaceuticals, Inc.

FAQ

When will NeuroBo Pharmaceuticals present at the Emerging Growth Conference?

NeuroBo Pharmaceuticals will present at the Emerging Growth Conference on July 18, 2024, at 10:50 am ET.

What will NeuroBo Pharmaceuticals discuss at the conference on July 18, 2024?

NeuroBo Pharmaceuticals will provide an update on the clinical development of DA-1726, a novel dual oxyntomodulin (OXM) analog agonist for the treatment of obesity.

Who will represent NeuroBo Pharmaceuticals at the Emerging Growth Conference?

Hyung Heon Kim, President and CEO, and Marshall H. Woodworth, CFO, will represent NeuroBo Pharmaceuticals.

How can I ask questions during NeuroBo Pharmaceuticals' presentation at the conference?

Questions can be submitted in advance to questions@emerginggrowth.com or asked during the event.

Where can I register to attend NeuroBo Pharmaceuticals' presentation at the Emerging Growth Conference?

You can register to attend the virtual conference using the provided link in the announcement to receive updates.

What is the focus of DA-1726 discussed by NeuroBo Pharmaceuticals?

DA-1726 is a novel dual oxyntomodulin (OXM) analog agonist targeting the glucagon-like peptide-1 receptor (GLP1R) and glucagon receptor (GCGR) for obesity treatment.

How can I schedule a meeting with NeuroBo Pharmaceuticals' management outside of the conference?

To schedule a meeting with management, contact Michael Miller at mmiller@rxir.com.